Shots: The BLA submission is based on a P-III ORIENT-11 study assessing sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT as a 1L treatment for 397 patients […]readmore
Tags : Chemotherapy
Shots: The approval is based on P-III IMpower133 study assessing Tecentriq (atezolizumab) + CT (carboplatin and etoposide) vs CT as monothx. in 403 patients in ratio (1:1) in CT-naïve patients […]readmore
Shots: The approval is based on P-III KEYNOTE-189 trial assessing Keytruda + pemetrexed & Pt CT in patients with 1L metastatic non-sq NSCLC, with no EGFR or ALK genomic tumor […]readmore
Regulatory
Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s
Shots: The approval is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT as monothx. in 403 patients in ratio (1:1) with (ES-SCLC) The P-III IMpower133 study […]readmore
Shots: The approval is based on P-III KEYNOTE-407 study assessing Keytruda + carboplatin/nab paclitaxel vs carboplatin/nab paclitaxel monothx. in ratio (1:1) in patients with msqNSCLC regardless of PD-L1 expression The […]readmore
Shots: The P-III KEYNOTE-181 study involves assessing of Keytruda monothx vs CT in 600 patients in ratio (1:1) receiving (Keytruda 200 mg FD q3w) or IV CT (docetaxel /paclitaxel/ irinotecan) […]readmore